# Johnson & Johnson Reports High Long-Term Crohn's Remission Rates for Tremfya in Phase 3 Trials

- URL: https://stocks.freetheai.org/news/johnson-johnson-reports-high-long-term-crohn-s-remission-rates-for-tremfya-in-612ac0
- Published: 2026-10-12T21:16:32Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NYSE:JNJ](https://stocks.freetheai.org/symbols/NYSE-JNJ)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Johnson & Johnson (JNJ) announced long-term Phase 3 clinical data for Tremfya (guselkumab) showing high remission rates in adult patients with Crohn's disease over a three-year period. In the GALAXI 2 and GALAXI 3 studies, participants receiving 100 mg every eight weeks achieved a 94% clinical remission rate, while those receiving 200 mg every four weeks reached a 91% remission rate.

The findings highlight durable efficacy for the treatment across multiple clinical measures. Along with high overall remission, 88% of patients across both dosing schedules achieved 90-day corticosteroid-free clinical remission. Additionally, endoscopic remission was reached by 52% of participants on the eight-week regimen and 61% of those on the four-week schedule. In a separate Phase 3 trial named FUZION, Tremfya also demonstrated significantly higher combined fistula remission rates at 24 weeks compared to a placebo.

Investors and healthcare market participants will monitor ongoing clinical developments, regulatory updates, and potential commercial performance of Tremfya as additional subgroup evaluations and long-term data emerge.

## Key points

- Long-term Phase 3 trials GALAXI 2 and GALAXI 3 showed Tremfya delivered up to 94% clinical remission in Crohn's disease patients over three years.
- In the GALAXI trials, 52% of patients on an eight-week dosage and 61% on a four-week dosage reached endoscopic remission.
- Both dosage groups in the GALAXI study achieved an 88% rate of 90-day corticosteroid-free clinical remission.
- Phase 3 FUZION study results demonstrated higher combined fistula remission rates at week 24 for Tremfya compared to placebo.

## Questions and answers

### What were the three-year clinical remission rates for Tremfya in Crohn's disease patients?

Patients receiving 100 mg of Tremfya every eight weeks achieved a 94% clinical remission rate, while those treated every four weeks saw a 91% clinical remission rate over three years.

### How did Tremfya perform in corticosteroid-free remission?

In the GALAXI 2 and GALAXI 3 Phase 3 trials, 88% of patients in both dosing groups achieved 90-day corticosteroid-free clinical remission.

### What were the findings from the Phase 3 FUZION study?

Tremfya achieved combined fistula remission at week 24 in 28% of patients on the eight-week regimen and 27% on the four-week regimen, compared to 10% for placebo.